In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Regulus Therapeutics Inc. (NASDAQ:RGLS) reported that Broadfin Capital has picked up 5,494,505 of common stock as of 2017-07-24.
The acquisition brings the aggregate amount owned by Broadfin Capital to a total of 5,494,505 representing a 5.65% in the company.
For those not familiar with the company, Regulus Therapeutics Inc. is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state. The Company’s Regulus microMarkers division is focused on identifying microRNAs as biomarkers of human disease. It has a research collaboration with Biogen focused on the discovery of microRNAs as biomarkers for multiple sclerosis and has completed research for another pharmaceutical company to explore microRNAs as biomarkers for specific patient populations. The Company is developing RG-101, an N-Acetylgalactosamine (GalNAc)-conjugated anti-miR targeting miR-122; RG-012, an anti-miR targeting microRNA-21 for the treatment of Alport syndrome, and RG-125, a GalNAc-conjugated anti-miR targeting microRNA-103/107.
A glance at Regulus Therapeutics Inc. (NASDAQ:RGLS)’s key stats reveals a current market capitalization of 61.98 Million based on 97.18 Million shares outstanding and a price at last close of $1.15 per share.
Looking at insider activity, there are a few recent transactions worth noting.
Specifically, on 2017-03-22, Papadopoulos picked up 300,000 at a purchase price of $1.23.This brings their total holding to 700,677 as of the date of the filing.
On the sell side, the most recent transaction saw Isis unload 111,000 shares at a sale price of $10.21. This brings their total holding to 5,173,172.
It’s possible to gauge a company’s potential by tracking the activity of its major holders, as well as checking in on insider activity such as those transactions listed above. We’ll be keeping an eye on Regulus Therapeutics Inc. (NASDAQ:RGLS) as things move forward to see if its progress aligns with these transactions. Subscribe below and we’ll keep you on top of what’s happening before it moves markets.